Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Stage IV breast cancer~* Measurable disease~* Progressive disease~  * Increase in disease mass or less than partial response to therapy~ * At least one prior chemotherapy regimen for metastatic disease and progressed~    * Must have received prior therapy with a taxane and an anthracycline~* Estrogen/progesterone receptor-positive patients must have received and progressed on at least one hormonal agent in adjuvant or metastatic setting~* Her2-neu-expressing patients must have received and progressed on trastuzumab (Herceptin®) in adjuvant or metastatic setting~* Prior autologous stem cell transplantation allowed if less than complete response or disease progression in adjuvant or metastatic setting~* Consenting first-degree relative with at least 5 out of 6 HLA-antigen match (may include mismatch at the D locus)~* Hormone receptor status:~  * Estrogen receptor status known~ * Progesterone receptor status known~PATIENT CHARACTERISTICS:~Age:~* 18 to 70~Sex:~* Male or female~Menopausal status:~* Not specified~Performance status:~* Karnofsky 80-100%~Life expectancy:~* More than 6 months~Hematopoietic:~* Not specified~Hepatic:~* Bilirubin ≤ 2 mg/dL~* SGOT \< 4 times upper limit of normal~* Hepatitis B surface antigen negative~* Hepatitis C antibody negative~Renal:~* Creatinine ≤ 1.5 mg/dL~* Creatinine clearance ≥ 50 mL/min~Cardiovascular:~* Left ventricular ejection fraction \> 45%~Pulmonary:~* DLCO ≥ 50% of predicted~Other:~* HIV negative~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~* Recovered from prior stem cell transplantation~Chemotherapy:~* See Disease Characteristics~Endocrine therapy:~* See Disease Characteristics~* No concurrent steroids~Radiotherapy:~* Not specified~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).